- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00420082
A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber
April 4, 2012 updated by: Faes Farma, S.A.
A Randomized, Double-Blind, 4 Way Cross-over, Placebo Controlled Trial to Evaluate the Onset of Action of Bilastine 20 mg vs. Placebo, Cetirizine 10 mg, and Fexofenadine 120 mg in the Vienna Challenge Chamber
This is a randomized, double blind, active and placebo controlled, 4 way crossover study in patients with seasonal allergic rhinitis.
Patients will receive a single dose of bilastine 20 mg, Cetirizine 10 mg, Fexofenadine 120 mg, and placebo in the Vienna Challenge Chamber.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The objective of the study is to determine the effect of a single dose of bilastine 20 mg on nasal symptoms of allergic rhinitis provoked by spending 4 hours in the Vienna Challenge Chamber .
This effect will be compared to that action of Cetirizine 10 mg, Fexofenadine 120 mg, and placebo.
To explore the onset of action, patients will receive study drug two hours after the start of the provocation on Day 1.Patients will remain in theVCC for an additional four hours.
On Day 2, patients will return to the VCC post-dose hours 22-26.
Study Type
Interventional
Enrollment (Actual)
75
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Vienna, Austria, A-1150
- Allergy Center Vienna West
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Have a history of seasonal allergic rhinitis
- Have a positive (as defined in the protocol) skin prick or RAST test within 12 months prior to the screening visit
Exclusion Criteria:
- Have a clinically significant illness or disease
- Have unstable asthma
- Has participated in a clinical trial 30 days prior to the screening visit
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 4
Placebo
|
Encapsulated Placebo tablets Q.D.
|
Experimental: 1
Bilastine 20 mg
|
Encapsulated Bilastine 20 mg tablets Q.D.
|
Active Comparator: 2
Fexofenadine 120 mg
|
Encapsulated Fexofenadine 120 mg tablets Q.D.
Other Names:
|
Active Comparator: 3
Cetirizine 10 mg
|
Encapsulated Cetirizine 10 mg tablets Q.D.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Onset of action and action duration
|
Secondary Outcome Measures
Outcome Measure |
---|
FEV1
|
Nasal and ocular symptom scores
|
Nasal airflow resistance
|
Nasal secretion weight
|
Routine safety parameters (vital signs, ECGs, clinical laboratory tests)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Friedrich Horak, Professor, ENT University Clinic Vienna
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2006
Study Completion (Actual)
December 1, 2006
Study Registration Dates
First Submitted
January 8, 2007
First Submitted That Met QC Criteria
January 8, 2007
First Posted (Estimate)
January 9, 2007
Study Record Updates
Last Update Posted (Estimate)
April 5, 2012
Last Update Submitted That Met QC Criteria
April 4, 2012
Last Verified
April 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Immune System Diseases
- Hypersensitivity, Immediate
- Otorhinolaryngologic Diseases
- Respiratory Hypersensitivity
- Hypersensitivity
- Nose Diseases
- Rhinitis
- Rhinitis, Allergic
- Rhinitis, Allergic, Seasonal
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Allergic Agents
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Histamine H1 Antagonists, Non-Sedating
- Cetirizine
- Fexofenadine
Other Study ID Numbers
- BILA-2306/ACC
- 2006-003004-19 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Seasonal Allergic Rhinitis
-
Glenmark Specialty S.A.CompletedSeasonal Allergic Rhinitis (SAR)United States
-
UCB PharmaCompletedRhinitis | Allergic | Seasonal
-
UCB PharmaCompleted
-
Glenmark Specialty S.A.CompletedSeasonal Allergic Rhinitis (SAR)United States
-
SanofiCompleted
-
SanofiCompleted
-
BayerCompletedRhinitis | Seasonal Rhinitis
-
GlaxoSmithKlineCompletedRhinitis, Allergic, Perennial and SeasonalUnited States
-
University of East AngliaNorfolk and Norwich University Hospitals NHS Foundation Trust; Quadram Institute... and other collaboratorsCompletedAsthma | Grass Allergy | Seasonal Affective RhinitisUnited Kingdom
-
Organon and CoCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
Clinical Trials on Bilastine
-
Faes Farma, S.A.ORA, Inc.CompletedAllergic ConjunctivitisUnited States
-
The Affiliated Hospital of Qingdao UniversityNot yet recruiting
-
Faes Farma, S.A.CompletedChronic Urticaria | Allergic RhinoconjunctivitisAustralia, Germany, Sweden
-
Charite University, Berlin, GermanyFaes Farma, S.A.CompletedCold Contact UrticariaGermany
-
Faes Farma, S.A.Charles River Clinical Services Edinburgh Ltd and CR Laboratories Preclinical... and other collaboratorsCompleted
-
Faes Farma, S.A.Merck Sharp & Dohme LLC; Allied Research InternationalCompletedHypersensitivity | Allergic Conjunctivitis | Seasonal Allergic Rhinitis | Hay FeverUnited States
-
A.Menarini Asia-Pacific Holdings Pte LtdUnknownPharmacokineticsChina
-
Menarini International Operations Luxembourg SACompletedAllergic Rhinitis | UrticariaItaly
-
Charite University, Berlin, GermanyCompleted